About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Cystic Fibrosis Treatment Made Effective With Quorum-sensing Inhibitors

by Julia Samuel on December 18, 2017 at 3:37 PM
Font : A-A+

Cystic Fibrosis Treatment Made Effective With Quorum-sensing Inhibitors

Quorum-sensing inhibitors to current drugs not only reduces bacterial production of certain harmful residues but also restores the efficacy of existing treatments on the cells of cystic fibrosis patients.

Cystic fibrosis is a fatal genetic disease affecting children and adults. It is characterized by excessive mucus production in several organs, recurrent bacterial infections and progressive lung damage. To date, no cure has been found. When the disease is too far advanced, the only option is to perform a lung transplantation.

Advertisement


One of the difficulties encountered in cystic fibrosis research is the disease's variability from one patient to another. In fact, there are more than 2,000 possible gene mutations.

Over the past decade, two prescription medications have been offered to eligible patients:
  • Kalydeco for those with rare mutations (fewer than 4 percent of patients)
  • Orkambi for the more frequent mutation (79 percent of patients).
Unfortunately, these two drugs have only limited efficacy.
Advertisement

Brochiero's team is trying to understand why. With the consent of patients, she collects nasal cells and also reuses the lungs removed from patients with cystic fibrosis at the time of transplantation. To study the disease and test therapeutic approaches, the scientists then manage to recreate airway epithelial tissue, via tissue engineering.

"Patients with cystic fibrosis present genetic defects that cause the abnormal production of a protein called CFTR in cells and an excess of mucus in organs," said Emmanuelle Brochiero.

Current drugs act to correct the defect in the CFTR protein. In a sterile in vitro environment, Kalydeco and Orkambi treatments work well. But in real life, the lungs of sick patients are colonized by bacteria, Pseudomonas aeruginosa in particular.

Much evidence has indicated that the bacteria could interfere with the treatment. Thanks to this study, we have been able to determine which substances released by the bacteria could reduce the efficacy of the treatments.

Some of these harmful particles are controlled by the bacterial quorum-sensing gene lasR. "During the disease, this bacterial gene mutates and the production of harmful products varies," said Émilie Maillé, a research assistant in Brochiero's laboratory and the study's lead author.

"Our work confirms that different bacterial strains, depending on whether they come from acute infections - especially in young patients - or chronic infections - especially in older patients - affect treatment efficacy in different ways."

The research team then tested, in vitro, the effect of adding a quorum-sensing inhibitor from the furanone family. "We showed that this molecule, by reducing the bacterial production of harmful residues, maintains treatment efficacy in the cells of patients with cystic fibrosis," Brochiero said.

Other research has to be conducted to confirm the efficacy and safety of quorum-sensing inhibitors, which may eventually be offered as a supplement to the current (Kalydeco and Orkambi) treatments.

But this study has already opened a new personalized-medicine avenue to cystic fibrosis. "By using cells collected from patients, we think that it will be possible to test and predict the efficacy of treatments such as Kalydeco and Orkambi, on cells collected from the patient, in the presence of the bacteria taken from the same patient," concluded Brochiero.

"We'll also evaluate the ability of the treatments to repair damaged lung tissue. And lastly, we'll work on identifying the most effective molecules, such as bacterial quorum-sensing inhibitors, that can counteract the harmful effect of infections. The ultimate goal is to improve treatments for patients and, by doing so, extend their life."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Genetic Testing of Diseases Cystic Fibrosis Fibroscan for Fatty Liver Cirrhosis and Fibrosis Retroperitoneal Fibrosis / Ormondīs Disease 

Recommended Reading
Cystic Fibrosis
Cystic fibrosis is a genetic disease involving the mucus and sweat glands and the medical world has ...
Respiratory Diseases
Respiratory diseases affect any part of the respiratory system. Some of the lung diseases like ......
Now a Wearable Sweat Sensor Band is Here to Help Diagnose Cystic Fibrosis
A wristband-type wearable sweat sensing band can help in the quick analysis of sweat and easy ......
Cystic Fibrosis-Possible Treatment Target Identified
In cystic fibrosis, the compact mucin protein that keeps mucus too thick and sticky, causing ......
Fibroscan for Fatty Liver Cirrhosis and Fibrosis
Recently, Fibroscan has incorporated the noninvasive Controlled Attenuation Parameter technique to e...
Genetic Testing of Diseases
Genetic testing helps to confirm a genetic condition in an individual and involves q complex laborat...
Retroperitoneal Fibrosis / Ormondīs Disease
Retroperitoneal fibrosis or Ormond's disease a rare disorder occurs when extra fibrous tissue forms ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use